{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:30:22Z","timestamp":1778509822967,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,1,15]],"date-time":"2016-01-15T00:00:00Z","timestamp":1452816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00520-016-3075-8","type":"journal-article","created":{"date-parts":[[2016,1,15]],"date-time":"2016-01-15T12:59:36Z","timestamp":1452862776000},"page":"2381-2392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis"],"prefix":"10.1007","volume":"24","author":[{"given":"Leonard","family":"Chiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolph M.","family":"Navari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan M.","family":"Shumway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milica","family":"Milakovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Pasetka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherlyn","family":"Vuong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,15]]},"reference":[{"issue":"4","key":"3075_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s005200050078","volume":"5","author":"D Osoba","year":"1997","unstructured":"Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 5(4):307\u2013313","journal-title":"Support Care Cancer"},{"key":"3075_CR2","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetic American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189\u201398","journal-title":"J Clin Oncol"},{"issue":"4","key":"3075_CR3","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00520-014-2138-y","volume":"22","author":"CM Hocking","year":"2014","unstructured":"Hocking CM, Kichenadasse G (2014) Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer 22(4):1143\u20131151","journal-title":"Support Care Cancer"},{"issue":"6","key":"3075_CR4","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0885-3924(03)00143-X","volume":"25","author":"M Srivastava","year":"2003","unstructured":"Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R (2003) Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manag 25(6):578\u2013582","journal-title":"J Pain Symptom Manag"},{"issue":"7","key":"3075_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00520-004-0755-6","volume":"13","author":"RM Navari","year":"2005","unstructured":"Navari RM, Einhorn LH, Passik SD, Loehrer PJ, Johnson C, Mayer ML et al (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 13(7):529\u2013534","journal-title":"Support Care Cancer"},{"issue":"3","key":"3075_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1081\/CNV-200029066","volume":"22","author":"SD Passik","year":"2004","unstructured":"Passik SD, Navari RM, Jung SH, Nagy C, Vinson J, Kirsh KL et al (2004) A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Investig 22(3):383\u2013388","journal-title":"Cancer Investig"},{"issue":"5","key":"3075_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0885-3924(03)00078-2","volume":"25","author":"SD Passik","year":"2003","unstructured":"Passik SD, Kirsh KL, Theobald DE, Dickerson P, Trowbridge R, Gray D et al (2003) A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manag 25(5):485\u2013488","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"3075_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S0885-3924(02)00391-3","volume":"23","author":"SD Passik","year":"2002","unstructured":"Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E et al (2002) A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag 23(6):526\u2013532","journal-title":"J Pain Symptom Manag"},{"issue":"11","key":"3075_CR9","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00520-007-0248-5","volume":"15","author":"RM Navari","year":"2007","unstructured":"Navari RM, Einhorn LH, Loehrer PJ, Passik SD, Vinson J, McClean J et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 15(11):1285\u20131291","journal-title":"Support Care Cancer"},{"issue":"3","key":"3075_CR10","first-page":"349","volume":"97","author":"S Chanthawong","year":"2014","unstructured":"Chanthawong S, Subongkot S, Sookprasert A (2014) Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting. J Med Assoc Thail = Chotmaihet Thangphaet 97(3):349\u2013355","journal-title":"J Med Assoc Thail = Chotmaihet Thangphaet"},{"key":"3075_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1756-9966-28-131","volume":"28","author":"L Tan","year":"2009","unstructured":"Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, Zhang D (2009) Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:131","journal-title":"J Exp Clin Cancer Res"},{"key":"3075_CR12","doi-asserted-by":"crossref","unstructured":"Shumway NM, Terrazzino SE, Jones CB (2009) A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy-induced nausea and vomiting. J Clin Oncol: Ann ASCO Meet 27(15)","DOI":"10.1200\/jco.2009.27.15_suppl.9633"},{"issue":"6","key":"3075_CR13","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","volume":"21","author":"RM Navari","year":"2013","unstructured":"Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21(6):1655\u20131663","journal-title":"Support Care Cancer"},{"issue":"5","key":"3075_CR14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9(5):188\u2013195","journal-title":"J Support Oncol"},{"key":"3075_CR15","doi-asserted-by":"crossref","unstructured":"Navari RM, Gray SE (2009) Treatment of chemotherapy-induced breakthrough nausea and vomiting. Conference publication: 2009 annual meeting of the American Society of Clinical Oncology","DOI":"10.1037\/e548132012-205"},{"issue":"3","key":"3075_CR16","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jpainsymman.2013.05.003","volume":"47","author":"N Mizukami","year":"2014","unstructured":"Mizukami N, Yamauchi M, Koike K, Watanabe A, Ichihara K, Masumori N et al (2014) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manag 47(3):542\u2013550","journal-title":"J Pain Symptom Manag"},{"key":"3075_CR17","first-page":"7406","volume":"6","author":"X Wang","year":"2012","unstructured":"Wang X, Wang L (2012) Effectiveness of olanzapine in prevention of chemotherapy induced nausea and vomiting. Clin J Clin (Electron Ed) 6:7406\u20137407","journal-title":"Clin J Clin (Electron Ed)"},{"key":"3075_CR18","first-page":"452","volume":"13","author":"WK Mao","year":"2011","unstructured":"Mao WK, Peng L (2011) Clinical observation of Olanzapine combined with Granisetrom and Hexadecadrol prevent nausea vomit induced by chemoradiotherapy. Chin J Med Guid 13:452\u2013454","journal-title":"Chin J Med Guid"},{"key":"3075_CR19","first-page":"544","volume":"20","author":"YL Lu","year":"2013","unstructured":"Lu YL et al (2013) Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Clin J Cancer Prev Treat 20:544\u2013554","journal-title":"Clin J Cancer Prev Treat"},{"key":"3075_CR20","doi-asserted-by":"crossref","unstructured":"Navari RM, Gray S (2010) Treatment of chemotherapy-induced breakthrough nausea and vomiting. Conference publication: 7th annual conference of the American Psychosocial Oncology Society","DOI":"10.1037\/e548132012-205"},{"key":"3075_CR21","doi-asserted-by":"crossref","unstructured":"Navari RM, Nagy CK (2015) Olanzapine versus fosaprepitant for the prevention of nausea and vomiting in patients receiving concurrent chemo-radiation treatment. Conference publication: 2015 annual meeting of the American Society of Clinical Oncology","DOI":"10.1200\/jco.2015.33.15_suppl.9502"},{"key":"3075_CR22","doi-asserted-by":"crossref","unstructured":"Mukhopadhyay S, Kwartra G, Jeyaraj P, Badyal D (2015) Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients: a randomized controlled study. Conference publication: MASCC\/ISOO Annual Meeting on Supportive Care in Cancer","DOI":"10.1007\/s00520-016-3386-9"},{"key":"3075_CR23","doi-asserted-by":"publisher","unstructured":"Wang X, Wang L, Wang H, Zhang H (2015) Effectiveness of olanzapine combined with ondansetron in prevention of chemotherapy-induced nausea and vomiting of non-small cell lung cancer. Cell Biochem Biophys 1\u20133","DOI":"10.1007\/s12013-014-0489-0"},{"key":"3075_CR24","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1038\/srep04813","volume":"4","author":"XF Wang","year":"2014","unstructured":"Wang XF, Feng Y, Chen Y, Gao BL, Han BH (2014) A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Sci Rep 4:4813","journal-title":"Sci Rep"},{"issue":"Suppl 5","key":"3075_CR25","doi-asserted-by":"publisher","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","volume":"21","author":"F Roila","year":"2010","unstructured":"Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232\u2013v243","journal-title":"Ann Oncol"},{"issue":"12","key":"3075_CR26","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1002\/cncr.11433","volume":"97","author":"S Poli-Bigelli","year":"2003","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study G (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090\u20133098","journal-title":"Cancer"},{"issue":"6","key":"3075_CR27","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/annonc\/mdl019","volume":"17","author":"HJ Schmoll","year":"2006","unstructured":"Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, von Pawel J, Giezek H, Ahmed T, Chan CY (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17(6):1000\u20131006","journal-title":"Ann Oncol"},{"key":"3075_CR28","doi-asserted-by":"publisher","unstructured":"Aapro M, Rossi G, Rizzi G, Palmas M, Grunberg S (2013) Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy induced nausea and vomiting (CINV) following moderately emetic chemotherapy (MEC). 2013 ASCO Annual Meeting Abstract LBA9514. Presented June 1st 2013","DOI":"10.1200\/jco.2013.31.18_suppl.lba9514"},{"issue":"5","key":"3075_CR29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","volume":"15","author":"L Cohen","year":"2007","unstructured":"Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497\u2013503","journal-title":"Support Care Cancer"},{"issue":"4","key":"3075_CR30","doi-asserted-by":"crossref","first-page":"456","DOI":"10.6004\/jnccn.2012.0047","volume":"10","author":"DS Ettinger","year":"2012","unstructured":"Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B et al (2012) Antiemesis. J Natl Compr Cancer Netw 10(4):456\u2013485","journal-title":"J Natl Compr Cancer Netw"},{"key":"3075_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","volume":"14","author":"FP Bymaster","year":"1996","unstructured":"Bymaster FP, Calligaro D, Falcone J et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87\u201396","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"3075_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.critrevonc.2015.02.010","volume":"95","author":"C Fonte","year":"2015","unstructured":"Fonte C, Fatigoni S, Roila F (2015) A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients. Crit Rev Oncol\/Hematol 95(2):214\u2013221","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"suppl 12","key":"3075_CR33","first-page":"5","volume":"64","author":"J Kane","year":"2003","unstructured":"Kane J, Stefan L, Carpenter D, Docherty J (2003) Introduction: methods, commentary, and summary. J Clin Psychiatr 64(suppl 12):5\u201319","journal-title":"J Clin Psychiatr"},{"issue":"suppl 10","key":"3075_CR34","first-page":"45","volume":"58","author":"CB Nemeroff","year":"1997","unstructured":"Nemeroff CB (1997) Dosing the antipsychotic medication olanzapine. J Clin Psychiatr 58(suppl 10):45\u20139","journal-title":"J Clin Psychiatr"},{"key":"3075_CR35","first-page":"443","volume":"58","author":"AS Hale","year":"1997","unstructured":"Hale AS (1997) Olanzapine. Br J Hosp Med 58:443\u2013445","journal-title":"Br J Hosp Med"},{"key":"3075_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-244X-10-43","volume":"10","author":"H Detke","year":"2010","unstructured":"Detke H, McDonnell D, Brunner E et al (2010) Post-injection delirium\/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 10:43","journal-title":"BMC Psychiatry"},{"issue":"3","key":"3075_CR37","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0735-6757(02)42249-8","volume":"21","author":"J Battaglia","year":"2003","unstructured":"Battaglia J, Lindborg S, Alaka K et al (2003) Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 21(3):192\u2013198","journal-title":"Am J Emerg Med"},{"key":"3075_CR38","unstructured":"National Comprehensive Cancer Network (2014) NCCN guidelines version 1.2014 www.nccn.org. Accessed 7 July 2015"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3075-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-016-3075-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3075-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3075-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T01:09:42Z","timestamp":1600045782000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-016-3075-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,15]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["3075"],"URL":"https:\/\/doi.org\/10.1007\/s00520-016-3075-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,15]]}}}